普華和順(01358.HK)中期淨利上升135.8%至1.412億元
格隆匯 8 月 27日丨普華和順(01358.HK)發佈公告,截至2020年6月30日止六個月,收入同比下跌41.1%至約人民幣1.015億元;毛利同比下跌44.2%至約人民幣5950萬元;公司擁有人應占溢利同比上升135.8%至約人民幣1.412億元;每股基本盈利人民幣8.99分。
公告表示,集團的收入下跌由於輸液器業務銷售額下跌所致。該下跌主要由於2020年初開始的新冠疫情爆發令醫院人流大幅減少,導致輸液器銷量下跌(於集團的主要銷售地區如北京、湖北及黑龍江尤甚);及一次性靜脈留置針銷售額增加43.9%至人民幣2390萬元,抵減了部分輸液器銷量下跌產生的負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.